Bayer (BAYN) Given a €125.00 Price Target at UBS Group
Bayer (FRA:BAYN) received a €125.00 ($154.32) target price from investment analysts at UBS Group in a report issued on Monday, www.boersen-zeitung.de reports. The firm currently has a “buy” rating on the healthcare company’s stock. UBS Group’s target price suggests a potential upside of 27.55% from the stock’s previous close.
A number of other research firms have also recently issued reports on BAYN. Deutsche Bank set a €124.00 ($153.09) price objective on shares of Bayer and gave the stock a “buy” rating in a research report on Friday, October 27th. Berenberg Bank set a €124.00 ($153.09) price objective on shares of Bayer and gave the stock a “neutral” rating in a research report on Tuesday, December 5th. Warburg Research set a €121.00 ($149.38) price objective on shares of Bayer and gave the stock a “neutral” rating in a research report on Thursday, January 11th. JPMorgan Chase & Co. set a €128.00 ($158.02) price objective on shares of Bayer and gave the stock a “buy” rating in a research report on Thursday, January 4th. Finally, Societe Generale set a €117.00 ($144.44) price objective on shares of Bayer and gave the stock a “neutral” rating in a research report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the stock. Bayer presently has a consensus rating of “Buy” and a consensus target price of €121.71 ($150.26).
Bayer (FRA:BAYN) opened at €98.00 ($120.99) on Monday. The stock has a market cap of $81,670.00 and a PE ratio of 23.17. Bayer has a 1 year low of €93.30 ($115.19) and a 1 year high of €123.82 ($152.86).
COPYRIGHT VIOLATION NOTICE: This article was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://theolympiareport.com/2018/02/12/bayer-bayn-given-a-125-00-price-target-at-ubs-group.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.